rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

TuHURA Biosciences, Inc.

HURA · Nasdaq

Health CareBiotechnologyNot moving yet

HURA stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 19.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 6
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
3
Institutions holding
85 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

3 disclosed lines: House 3, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Laurel M. Lee House: U.S. House ClerkFL15boughtspouse$50k–$100k13 Jul 2025filed 9 Aug 2025
Laurel M. Lee House: U.S. House ClerkFL15boughtspouse$1k–$15k25 Nov 2024filed 7 Jan 2025
Laurel M. Lee House: U.S. House ClerkFL15exchangedspouse$100k–$250k18 Oct 2024filed 21 Nov 2024

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders85+4 on the quarter
New · exited24 · 21
Reported value$20.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,267,901$5.3M+193,673+9.3%
NORTHERN TRUST CORPadded · filed 13 Aug 20261,621,042$3.8M+1,322,855+443.6%
BlackRock, Inc.reduced · filed 7 Aug 2026690,088$1.6M-1,760,168−71.8%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026484,219$1.1M-502,703−50.9%
MILLENNIUM MANAGEMENT LLCnew · filed 14 Aug 2026454,535$1.1M+454,535
AQR CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 2026424,600$994K-182,568−30.1%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 2026251,186$588K-35,947−12.5%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026232,319$544K+232,319
STATE STREET CORPreduced · filed 7 Aug 2026188,404$441K-324,509−63.3%
JANE STREET GROUP, LLCnew · filed 14 Aug 2026163,891$384K+163,891
31 Dec 2024 – 30 Jun 2026
275583Dec 24Jun 25Sep 25Mar 26Jun 26

Everyone who traded it

James A. Bianco Company insiderChief Executive Officer · last 28 May 20260 · 0
Alan List Company insiderDirector · last 12 Feb 20260 · 0
Craig Tendler Company insiderDirector · last 12 Feb 20260 · 0
George K. Ng Company insiderDirector · last 12 Feb 20260 · 0
James S. J. Manuso Company insiderDirector · last 12 Feb 20260 · 0
Robert E. Hoffman Company insiderDirector · last 12 Feb 20261 · 0
Dan Dearborn Company insiderChief Financial Officer · last 6 Jan 20260 · 0
Laurel M. Lee HouseFL15 · last 13 Jul 20252 · 0
Dennis Yamashita Company insiderChief Scientific Officer · last 18 Oct 20240 · 0
Dennis M. Brown Company insiderChief Scientific Officer · last 30 Aug 20234 · 0
Laura L. Johnson Company insiderDirector · last 30 Aug 20231 · 0
Robert Joseph Toth, Jr. Company insiderDirector · last 30 Aug 20234 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 23 Mar 20267.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$3.6M
Free cash flowFY 2025 · to 31 Dec 2025−$27.7M

Analyst forecasts

No analyst forecasts yet.